Physician profile
Peter John Sharis
NPI 1275512154
$1,334.31
in general payments reported to CMS, 2019-2025
16 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.09 · 2020: $243 · 2021: $99.25 · 2022: $59.80 · 2023: $50.39 · 2024: $193 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $278.43 | 2023-2025 | Impella |
| Astellas Pharma US INC | $199.98 | 2020 | |
| Abbott Laboratories | $195.90 | 2021-2025 | Assurity, Xience Sierra, Pressurewire |
| Novartis Pharmaceuticals Corporation | $191.26 | 2024-2025 | |
| Boston Scientific Corporation | $159.75 | 2025 | Farapulse, Ekosonic |
| Livanova USA, INC. | $56.09 | 2019 | |
| Alnylam Pharmaceuticals INC. | $48.84 | 2025 | Onpattro |
| Inari Medical, INC. | $43.33 | 2020 | |
| Chiesi USA, INC. | $35.80 | 2025 | Kengreal, Cleviprex |
| Penumbra, INC. | $25.58 | 2025 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $20.68 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $18.38 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.14 | 2023-2025 | Lifevest |
| Amgen INC. | $15.15 | 2025 | Repatha |
| Shockwave Medical, INC | $14.62 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sharis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.